In concert with partner Senseonics Holdings, Ascensia Diabetes Care announced that the U.S. Food and Drug Administration signed off on the Eversense E3 Continuous Glucose Monitoring System (CGM) System.
Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.
The U.S. FDA approved Senseonics Holdings’ Premarket Approval application to market the company’s Eversense Continuous Glucose Monitoring System to people with diabetes.
Abbott Laboratories said its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.
Smart Meter LLC received 510(k) clearance from FDA and CE Mark in Europe to market the company’s iGlucose Blood Glucose Monitoring System.